2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1781

Pituitary Disease and Granulomatosis with Polyangiitis: A Collaborative Canadian Case Series and Review of the Literature
Abstract Number: 2708

Placental Growth Factor Regulates the Generation of T-Helper 17 Cells to Link Angiogenesis with Autoimmunity
Abstract Number: 2600

Plasma Cell and T-Cell Activity Downregulation during MMF Therapy in SLE May be Necessary for Successful Immunosuppression
Abstract Number: 1281

Plasma CXCL4 As a Biomarker in Juvenile Systemic Sclerosis
Abstract Number: 466

Plasma Cytokines at Diagnosis May Predict Non-Response to Methotrexate in Patients with Early Rheumatoid Arthritis
Abstract Number: 2690

Plasma D-Dimer Levels Are More Frequently Elevated in Limited Than Diffuse Cutaneous Systemic Sclerosis but Do Not Reflect Disease Duration or Vasculopathy
Abstract Number: 2338

Plasma Exosomes from Children with Juvenile Dermatomyositis Are Taken up By Human Aortic Endothelial Cells and Are Associated with Altered Gene Expression in Those Cells
Abstract Number: 757

Plasmacytoid Dendritic Cells Activated through TLR8 Promote Systemic Sclerosis
Abstract Number: 2776

Plasmacytoid Dendritic Cells in Systemic Fibrosis: Pathogenic Role in Bleomycin-Induced Fibrosis Model and Correlation with Disease in Patients with Systemic Sclerosis
Abstract Number: 77

Platelets Induce IL-1b Production in Human Monocytes through NLRP3 Inflammasome Activation
Abstract Number: 2606

Pneumococcal Vaccination in Patients with Systemic Lupus Erythematosus: A Multicenter Placebo-Controlled Randomized Double-Blind Study
Abstract Number: 2026

Pneumococcal Vaccination Rates: Improving Safety in Immunocompromised Patients
Abstract Number: 53

Poly-γ-Glutamic Acid Inhibits RANKL- Induced Osteoclast Differentiation and Prevents Bone Destruction in Rheumatoid Arthritis: Human and CIA Mouse Model
Abstract Number: 1303

Polycystic Ovarian Syndrome in Rheumatic Disease
Abstract Number: 2365

Poor Cardiovascular Risk Management in Rheumatoid Arthritis Patients Despite an Explicit Cardiovascular Risk Management Program

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].